阿奇霉素与红霉素治疗小儿支原体肺炎的综合评价

Synthetic evaluation on intravenous azithromycin and erythromycin in treatment of mycoplasma pneumonia infections of childhood

目的:建立阿奇霉素与红霉素治疗小儿支原体肺炎的综合评价方法。方法:考察阿奇霉素与红霉素治疗小儿支原体肺炎的临床疗效和药物不良反应,用成本—效果分析的方法分析2种药物的经济性,最后用层次分析法进行综合评价。结果:阿奇霉素和红霉素组72h内体温恢复正常率分别为85%和63%(χ2=4.04,P<0.05),不良反应发生率分别为7%和39%(χ2=9.84,P<0.01),总有效率分别为98%和95%(χ2=0.0045,P>0.05),成本—效果比分别为192.43和318.69,评价权重分别为0.759868和0.240132,药物疗效、成本—效果比和药物不良反应的评价权重分别为0.571626、0.240919、0.187455,通过一次性检验(CI<0.1,CR<0.1),综合评价值分别为73.23和26.77。结论:阿奇霉素的综合评价效果明显优于红霉素。

Objiective: To make an synthetic evaluation on the clinical efficacy, safety and economic issues of intravenous azithromycin and erythromycin respectively in the therapy of lower respiratory tract infections. Methods: To observe the efficacy and adverse reactions of azithromycin and erythromycin in the treatment of lower respiratory tract infections by a randomized, controlled, multicenter study. To analyses the economic issues of azithromycin and erythromycin respectively by cost-effectiveness analysis. To comprehensively evaluate azithromycin and erythromycin by Analytic Hierarchy Process (AHP). Results: The evaluation weights of azithromycin and erythromycin are 0.759868 and 0.240132 respectively; The evaluation weights of efficacy, cost-effectiveness ratio and adverse reactions are 0.571626, 0.240919 and 0.187455 respectively. Identical test was qualified(CI < 0.1, CR < 0.1); Comprehensive evaluation weights of azithromycin and erythromycin are 78.71 and 21.29 respectively. Conclusion: The comprehensive evaluation weight of azithromycin is better than erythromycin's.